Last reviewed · How we verify
NCT00001686
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
trial in Ewing's Sarcoma in 482 participants. Completed in 2 September 2020.
2 September 2020
Quick facts
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 482 |
| Start date | 19 March 1998 |
| Primary completion | 2 September 2020 |
| Estimated completion | 2 September 2020 |
| Sites | 1 location across United States |
Conditions studied
- Ewing's Sarcoma — all drugs for Ewing's Sarcoma →
- Leukemia — all drugs for Leukemia →
- Lymphoma — all drugs for Lymphoma →
- Brain Tumors — all drugs for Brain Tumors →
Sponsor
National Cancer Institute (NCI)
Who can join
Adults 2 to 40, any sex, with Ewing's Sarcoma or Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This protocol is designed to evaluate children with cancer who appear to be probable candidates for future protocol entry or have disease manifestations that are of unique scientific importance or educational value.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00001686
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ewing's Sarcoma
Currently open trials in the same condition.
- NCT04671693 — A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Sur · NA · active not recruiting
- NCT03442465 — Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas · recruiting
Other National Cancer Institute (NCI) trials
Trials by the same sponsor.
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
- NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
- NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
- NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00001686 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
- Last refreshed: 10 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001686.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing